USPTO Examiner NIEBAUER RONALD T - Art Unit 1658

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18912061INSECT NEUROPEPTIDES 6October 2024May 2025Allow711YesNo
18906616BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4October 2024September 2025Allow1221YesNo
18660826CELL PENETRATING PEPTIDEMay 2024October 2025Allow1710NoNo
18426692READY-TO-USE BIVALIRUDIN COMPOSITIONSJanuary 2024September 2025Allow2011NoNo
18411838ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAMEJanuary 2024February 2026Abandon2521NoNo
18405731IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCERJanuary 2024April 2025Abandon1510NoNo
18513026NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENTNovember 2023April 2025Abandon1710NoNo
18506719INTRANASAL DESMOPRESSIN ADMINISTRATIONNovember 2023December 2025Abandon2511NoNo
18496597METHOD FOR ADJUSTING A PARENTERAL SUPPORT (PS) VOLUME IN A HUMAN SUBJECTOctober 2023January 2025Abandon1521NoNo
18491976INSECT NEUROPEPTIDES 6October 2023July 2024Allow911YesNo
18241549GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTIONSeptember 2023February 2026Abandon3021NoNo
18349855FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A pH-TRIGGERED POLYPEPTIDEJuly 2023January 2025Allow1810NoNo
18144387PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOFMay 2023March 2025Allow2211NoNo
18308695POLYPEPTIDE AND APPLICATION THEREOF IN BONE REPAIRApril 2023January 2024Allow811YesNo
18128799IDENTIFYING NEW THERAPEUTIC AGENTSMarch 2023August 2024Abandon1601NoNo
18120648DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIAMarch 2023October 2025Abandon3111NoNo
18172938METHOD OF REDUCING BISPECIFIC T CELL ENGAGER OR CHIMERIC ANTIGEN RECEPTOR T CELL MEDIATED CYTOKINE RELEASE SYNDROME USING INTERLEUKINS-4, -10, OR A FUSION PROTEIN THEREOFFebruary 2023December 2024Abandon2201YesNo
18168570METHODS AND COMPOSITIONS FOR TREATING HYPOGLYCEMIC DISORDERSFebruary 2023May 2025Abandon2711NoNo
18103694CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOFJanuary 2023October 2024Allow2121NoNo
18160807METHODS FOR PREVENTING FUNGAL INFECTIONSJanuary 2023July 2025Abandon3011NoNo
18094167CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAMEJanuary 2023October 2024Allow2121YesNo
18060523READY-TO-USE BIVALIRUDIN COMPOSITIONSNovember 2022January 2024Allow1321NoNo
18060529READY-TO-USE BIVALIRUDIN COMPOSITIONSNovember 2022January 2024Allow1311NoNo
17996330SETD7 EPIGENETIC MODULATORSOctober 2022March 2026Abandon4101NoNo
17894545METHOD FOR TREATMENT OF TYPE-1 DIABETES IN A SUBJECT IN NEED THEREOFAugust 2022September 2024Abandon2521YesNo
17820013ANTIMICROBIAL AND ANTICANCER PEPTIDES & CONJUGATES AND COMPOSITIONS, METHODS, ARTICLES & KITS RELATING THERETOAugust 2022April 2025Abandon3231NoNo
17817537SINGLE DOSE METHODS FOR PREVENTING AND TREATING FUNGAL INFECTIONSAugust 2022April 2024Abandon2101NoNo
17866905METHOD FOR PREPARING ETELCALCETIDE HYDROCHLORIDEJuly 2022October 2024Allow2731NoNo
17855372COLLAGEN MIMICSJune 2022April 2025Abandon3421NoNo
17809940SYNTHETIC PEPTIDE SP2 AND APPLICATION THEREOFJune 2022July 2024Allow2421YesNo
17854647CELL PENETRATING PEPTIDEJune 2022February 2024Allow1911YesNo
17846990PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOFJune 2022October 2023Abandon1621NoNo
17843079CYCLOSPORIN DERIVATIVES AND USES THEREOFJune 2022July 2025Abandon3721NoNo
17841929ISOLATED PEPTIDE, ANTI-CANCER MEDICINAL COMPOSITION INCLUDING THE SAME AND METHOD OF SPECIFICALLY REDUCING OR INHIBITING ACTIVITIES OF CANCER CELLS USING THE SAMEJune 2022October 2023Allow1610NoNo
17663188CYCLOSPORIN COMPOSITIONSMay 2022January 2024Abandon2001NoNo
17730960COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASESApril 2022May 2025Abandon3621NoNo
17770122Peptides with cell damage protection activity and liposomial formulationsApril 2022December 2025Abandon4401NoNo
17767302CYCLIC PEPTIDE COMPOUND CONTAINING PIPERAZIC ACID, METHOD OF PRODUCING SAME, AND USES OF SAMEApril 2022February 2026Abandon4611NoNo
17709917PROTEIN-WIDE MODIFICATION OF ASPARTATES AND GLUTAMATESMarch 2022April 2025Abandon3731NoNo
17656347Synthetic peptide sp4 and use thereofMarch 2022November 2023Allow1911NoNo
17698526IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCERMarch 2022November 2023Allow2011NoNo
17698531IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCERMarch 2022August 2023Allow1701NoNo
17691576IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCERMarch 2022November 2023Allow2111NoNo
17638038SELF-ASSEMBLING PEPTIDES, PREPARATION METHODS, SELF-ASSEMBLING PEPTIDE FORMULATIONS AND USEFebruary 2022January 2026Abandon4721NoNo
17677162COMPOSITION FOR TREATING CANCER EXPRESSING SPARCFebruary 2022December 2023Abandon2211NoNo
17635595TREATMENTFebruary 2022September 2025Abandon4301NoNo
17650894PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAMEFebruary 2022September 2024Abandon3131NoNo
17582445ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOFJanuary 2022August 2025Abandon4301NoNo
17627035EVOLVED BOTULINUM NEUROTOXINS AND USES THEREOFJanuary 2022February 2026Allow4921NoNo
17573317GIPR-AGONIST COMPOUNDSJanuary 2022October 2023Allow2111YesNo
17564893SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAMEDecember 2021May 2024Abandon2931NoNo
17620433PROCESS FOR THE MANUFACTURE OF GLUCAGONDecember 2021December 2025Abandon4821NoNo
17554134COLLAGEN-BASED MENISCUS IMPLANTSDecember 2021February 2026Allow5050NoNo
17618416INTRANASAL ADMINISTRATION OF MEROTOCIN FOR IMPROVING LACTATIONDecember 2021April 2025Abandon4010NoNo
17548044PEPTIDE AND USE THEREOFDecember 2021June 2025Abandon4211NoNo
17547076AMINO DEPROTECTION USING 3-(DIETHYLAMINO)PROPYLAMINEDecember 2021February 2023Allow1411YesNo
17530142ENDOLYSIN VARIANTNovember 2021September 2023Allow2211YesNo
17527807COMPOSITIONS FOR DIAGNOSIS, PREVENTION, OR TREATMENT OF FATTY LIVER DISEASENovember 2021January 2026Allow5051YesNo
17525023IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCERNovember 2021August 2023Allow2111NoNo
17603311METHODS OF OCULAR TREATMENT USING AN ENGINEERED DIMERIC FRAGMENT OF HEPATOCYTE GROWTH FACTOROctober 2021March 2025Abandon4101NoNo
17486602THERAPEUTIC COMPOUNDS AND METHODSSeptember 2021March 2023Allow1811NoNo
17410819SYNTHETIC HEME-CONTAINING MOLECULES AND THEIR USEAugust 2021September 2024Abandon3721YesNo
17400629THERAPEUTIC AGENT OF UREMIA CONTAINING ALARIN AS THE MAIN INGREDIENTAugust 2021February 2023Allow1810NoNo
17397539MOSQUITOCIDAL XENORHABDUS, LIPOPEPTIDE AND METHODSAugust 2021June 2024Abandon3421YesNo
17310536DECORATED INCLUSION BODY AND USES THEREOFAugust 2021June 2025Abandon4701NoNo
17389671ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAMEJuly 2021October 2023Allow2611YesNo
17377338PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNIIJuly 2021January 2024Allow3011NoNo
17421605CELL-PENETRATING PEPTIDESJuly 2021April 2025Allow4511YesNo
17358734PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOFJune 2021July 2023Abandon2501NoNo
17414103MITOCHONDRIA-TARGETING PEPTIDESJune 2021February 2025Allow4431YesNo
17348043FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORSJune 2021October 2024Allow4031YesNo
17333609COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLESMay 2021July 2024Abandon3701NoNo
17330798INTRANASAL DESMOPRESSIN ADMINISTRATIONMay 2021January 2024Abandon6011NoNo
17294527Composition and Method for Regulating Migration of Immune CellsMay 2021October 2024Abandon4101NoNo
17294011TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCERMay 2021August 2024Abandon3901NoNo
17319250FLAGELLIN COMPOSITIONS AND USESMay 2021July 2024Abandon3801NoNo
17243660Methods and Compositions for Oral Administration of ExenatideApril 2021January 2024Abandon3211NoNo
17240278MATRIPTASE AND U-PLASMINOGEN ACTIVATOR SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOFApril 2021September 2023Allow2911YesNo
17238932IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCERApril 2021July 2023Allow2611NoNo
17285188METHOD AND SYSTEM FOR TREATING CANCER UTILIZING TINAGL1April 2021March 2025Abandon4821NoNo
17227206SELENIUM-CHELATING PEA OLIGOPEPTIDE, AND PREPARATION METHOD AND USE THEREOFApril 2021January 2025Allow4551YesNo
17283997INHIBITORS OF PICK1 AND USES THEREOFApril 2021March 2025Abandon4731YesNo
17282514USE OF VEGF AT MULTIPLE DOSES TO ENHANCE PERMEABILITY OF BLOOD BRAIN BARRIERApril 2021January 2025Abandon4511NoNo
17281862Peptide Possessing Mesenchymal-Stem-Cell Mobilizing ActivityMarch 2021December 2024Abandon4531NoNo
17281942TELEOST INVARIANT CHAIN CANCER VACCINEMarch 2021January 2026Allow5941NoNo
17213472NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENTMarch 2021August 2023Allow2921YesNo
17280067NONAPEPTIDE PREVENTING INCREASED HYPERPERMEABILITY OF VASCULAR ENDOTHELIUMMarch 2021November 2023Abandon3121NoNo
17276101ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDEMarch 2021March 2024Allow3631YesNo
17199342MERS-COV INHIBITOR PEPTIDESMarch 2021October 2023Abandon3121YesNo
17270787METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRYFebruary 2021March 2026Abandon6031YesNo
17173917TANDEM REPEAT CANCER-TARGETING PEPTIDES FOR MOLECULAR CONJUGATION OR ENGINEERING AND USES THEREOF IN CANCER THERANOSTICSFebruary 2021February 2023Allow2411YesNo
17267914PROTEOGENOMIC-BASED METHOD FOR IDENTIFYING TUMOR-SPECIFIC ANTIGENSFebruary 2021January 2023Allow2411YesNo
17172202Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic PeptideFebruary 2021August 2023Allow3121YesNo
17265684COMBINATION THERAPIES COMPRISING TIM-3-BASED CHIMERIC PROTEINSFebruary 2021June 2024Abandon4001NoNo
17264277CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAMEJanuary 2021July 2023Abandon3021NoNo
17154097HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONSJanuary 2021October 2022Abandon2001NoNo
17153423HETEROCHIRAL PEPTIDE-COMPLEX AND COMPOSITION FOR MEASURING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY RESIDUAL DIPOLAR COUPLING CONTAINING SELF-ASSEMBLED INTERMEDIATES OF HETEROCHIRAL PEPTIDE-COMPLEXJanuary 2021November 2023Allow3431YesNo
17149583PEPTIDE/PARTICLE DELIVERY SYSTEMSJanuary 2021September 2025Allow5641YesNo
17259914PEPTOID-PEPTIDE MACROCYCLES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAMEJanuary 2021July 2024Allow4241YesNo
17136285CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINSDecember 2020July 2022Abandon1801NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NIEBAUER, RONALD T.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
11
Examiner Affirmed
5
(45.5%)
Examiner Reversed
6
(54.5%)
Reversal Percentile
80.8%
Higher than average

What This Means

With a 54.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
30
Allowed After Appeal Filing
7
(23.3%)
Not Allowed After Appeal Filing
23
(76.7%)
Filing Benefit Percentile
31.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NIEBAUER, RONALD T - Prosecution Strategy Guide

Executive Summary

Examiner NIEBAUER, RONALD T works in Art Unit 1658 and has examined 341 patent applications in our dataset. With an allowance rate of 52.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner NIEBAUER, RONALD T's allowance rate of 52.8% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NIEBAUER, RONALD T receive 2.16 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NIEBAUER, RONALD T is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +37.2% benefit to allowance rate for applications examined by NIEBAUER, RONALD T. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.5% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 12.6% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 57.7% of appeals filed. This is in the 31% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 90.0% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.